Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment

References

1. 1.↵
   2. Han BH,
   3. Li K,
   4. Zhao YZ,
   5. Li BL,
   6. Cheng Y,
   7. Zhou JY, et al.

   Anlotinib as a third-line therapy in patients with refractory advanced non-small cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018; 118: 654–61.

   OpenUrlCrossRefPubMed
2. 2.↵
   2. Sun YK,
   3. Niu W,
   4. Du F,
   5. Du CX,
   6. Li ST,
   7. Wang JW, et al.

   Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016; 9: 105.

   OpenUrl
3. 3.↵
   2. Lin BY,
   3. Song XM,
   4. Yang DW,
   5. Bai DS,
   6. Yao YY,
   7. Lu N.

   Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene. 2018; 654: 77–86.

   OpenUrlCrossRefPubMed
4. 4.↵
   2. Wilhelm SM,
   3. Adnane L,
   4. Newell P,
   5. Villanueva A,
   6. Llovet JM,
   7. Lynch M.

   Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008; 7: 3129–40.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   2. Shepherd F,
   3. Dancey J,
   4. Ramlau R,
   5. Mattson K,
   6. Gralla R,
   7. O'Rourke M, et al.

   Prospective randomized trial of docetaxel versus best supportive care in patients with non–small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18: 2095–103.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   2. Hanna N,
   3. Shepherd FA,
   4. Fossella FV,
   5. Pereira JR,
   6. De Marinis F,
   7. von Pawel J, et al.

   Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 1589–97.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   2. Shepherd FA,
   3. Rodrigues Pereira J,
   4. Ciuleanu T,
   5. Tan EH,
   6. Hirsh V,
   7. Thongprasert S, et al.

   Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2005; 353: 123–32.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   2. Yoshida T,
   3. Kuroda H,
   4. Oya Y,
   5. Shimizu J,
   6. Horio Y,
   7. Sakao Y, et al.

   Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure. Lung Cancer. 2017; 109: 89–91.

   OpenUrl
9. 9.↵
   2. Zhang K,
   3. Yuan Q.

   Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. J Cancer Res Ther. 2016; 12: C131–7.

   OpenUrl
10. 10.↵
    2. Ono A,
    3. Kenmotsu H,
    4. Watanabe M,
    5. Serizawa M,
    6. Mori K,
    7. Imai H, et al.

    Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation. Ann Oncol. 2014; 25: 1948–53.

    OpenUrlCrossRefPubMed
11. 11.↵
    2. Kimura K,
    3. Takayanagi R,
    4. Fukushima T,
    5. Yamada Y.

    Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment. Med Oncol. 2017; 34: 178.

    OpenUrl
12. 12.↵
    2. Zhao TT,
    3. Wang XN,
    4. Xu TT,
    5. Xu XD,
    6. Liu ZH.

    Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget. 2017; 8: 51492–506.

    OpenUrl
13. 13.↵
    2. Wang XY,
    3. Jiang RC,
    4. Li K.

    Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer. Cell Biochem Biophys. 2014; 69: 633–40.

    OpenUrl
14. 14.↵
    2. Li YY,
    3. Zhang CC,
    4. Wei XY,
    5. Wang XY,
    6. Li K.

    Base amount of blood T-lymphocyte subsets and NK cells in patients with lung cancer and its value in predicting prognosis. Chin J Clin Oncol. 2016; 43: 204–10.

    OpenUrl
15. 15.↵
    2. Meniawy TM,
    3. Lake RA,
    4. McDonnell AM,
    5. Millward MJ,
    6. Nowak AK.

    PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. Lung Cancer. 2016; 93: 9–16.

    OpenUrl
16. 16.↵
    2. Ho YS,
    3. Yip LY,
    4. Basri N,
    5. Chong VS,
    6. Teo CC,
    7. Tan E, et al.

    Lipidomic profiling of lung pleural effusion identifies unique metabotype for EGFR mutants in non-small cell lung cancer. Sci Rep. 2016; 6: 35110.

    OpenUrlCrossRef
17. 17.↵
    2. Li JJ,
    3. Yan H,
    4. Zhao L,
    5. Jia WZ,
    6. Yang H,
    7. Liu L, et al.

    Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells. Oncotarget. 2016; 7: 52392–403.

    OpenUrl
18. 18.↵
    2. Kasiske BL,
    3. de Mattos A,
    4. Flechner SM,
    5. Gallon L,
    6. Meier-Kriesche HU,
    7. Weir MR, et al.

    Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant. 2008; 8: 1384–92.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    2. Morrisett JD,
    3. Abdel-Fattah G,
    4. Hoogeveen R,
    5. Mitchell E,
    6. Ballantyne CM,
    7. Pownall HJ, et al.

    Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002; 43: 1170–80.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    2. Vergès B,
    3. Walter T,
    4. Cariou B.

    Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism. Eur J Endocrinol. 2014; 170: R43–R55.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    2. Yang W,
    3. Bai YB,
    4. Xiong Y,
    5. Zhang J,
    6. Chen SK,
    7. Zheng XJ, et al.

    Potentiating the antitumour response of CD8⁺ T cells by modulating cholesterol metabolism. Nature. 2016; 531: 651–5.

    OpenUrlCrossRefPubMed